Building Platform Strategies Instead Of One Off Vector Solutions

In this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, share lessons from their own organizations on balancing innovation with practical development. They discuss reusable vector platforms, collaboration across the industry, selecting existing capsids versus engineering new ones, partnering with CDMOs early, and integrating manufacturing considerations throughout product development.